Loading... Please wait...

Our Newsletter


Pemetrexed (LY-231514)

  • Pemetrexed (LY-231514) 200x200
  • Pemetrexed (LY-231514) 600x600
Price:
$109.00
Catalog #:
C5923-10
Quantity:


Product Description

Pemetrexed (LY-231514) is an antifolate that inhibits thymidylate synthase (TS) (Ki = 1.3 nM) and multiple folate-requiring enzymes, such as dihydrofolate reductase (DHFR) (Ki = 7.2 nM) and glycinamide ribonucleotide formyltransferase (GARFT) (Ki = 65 nM). [1]
Pemetrexed (LY-231514) has been studied as a potential treatment option in multiple tumor types, and has been approved in 2004 for the treatment of pleural mesothelioma [2] and non-small cell lung cancer (NSCLC) [3].
A recent clinical study reveals that platinum combination with Pemetrexed (LY-231514) significantly improved the disease control rate and resulted in a tendency toward prolongation of progression-free survival in NSCLC patients who progressed after first-line epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs). [4]"


Technical information:

Chemical Formula:   C20H19N5Na2O6
CAS #:   150399-23-8
Molecular Weight:   471.37
Purity:   > 98%
Appearance:   White
Chemical Name:   sodium (S)-2-(4-(2-(2-amino-4-oxo-4,7-dihydro-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl)benzamido)pentanedioate
Solubility:   Up to 100 mM in DMSO
Synonyms:   Pemetrexed, LY-231514, LY231514

Shipping Condition: The product is shipped in a glass vial at ambient temperature.
Storage condition: For longer shelf life, store solid powder or DMSO solution at -20oC desiccated.


Reference:

1. Shih C, et al. LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res. 1997. 57(6):1116-23. Pubmed ID: 9067281
2. Hazarika M, et al. FDA drug approval summaries: pemetrexed (Alimta). Oncologist. 2004. 9(5):482-8. Pubmed ID: 15477632
3. Cohen MH, et al. FDA drug approval summary: pemetrexed for injection (Alimta) for the treatment of non-small cell lung cancer. Oncologist. 2005. 10(6):363-8. Pubmed ID: 15967829
4. Lee SJ, et al. Pemetrexed plus platinum versus pemetrexed alone in non-small cell lung cancer patients who have progressed after first-line EGFR TKIs. Lung Cancer. 2015. 90(2):261-6. Pubmed ID: 15477632

Other Information:

Product Specification (pdf)
MSDS (pdf)
Certificate of Analysis is available upon request.

Find Similar Products by Category

Write your own product review

Product Reviews

This product hasn't received any reviews yet. Be the first to review this product!

Add to Wish List

Click the button below to add the Pemetrexed (LY-231514) to your wish list.

You Recently Viewed...



Online Payments